Latham & Watkins Advises on MapLight Therapeutics’ Initial Public Offering

MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, has announced the pricing of its initial public offering of 14,750,000 shares of common stock at an initial public offering price of US$17 per share. In addition, MapLight has granted the underwriters a 30-day option to purchase up to an additional 2,212,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP advised the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili and San Diego partner Matt Bush, with associates Sandy Kugbei, Akina Newbraugh, Kan Ni, and Skye Lee.